

Supplementary Table 1 | Evidence Behind the FDA Decision.

First Author	Population	Median follow-up	Treatment	Outcome	HR (95% CI)
(Keating et al. 2006)	73196 males with locoregional prostate cancer	4.6 y	Goserelin or	IHD	1.16 (1.10, 1.21)
			leuprorelin vs no	MI	1.11 (1.01, 1.21)
			ADT	SCD	1.16 (1.05, 1.27)
(Keating et al. 2010)	37443 males with locoregional prostate cancer	2.6 y	Goserelin or	IHD	1.19 (1.10, 1.28)
			leuprorelin vs no	MI	1.28 (1.08, 1.52)
			ADT	SCD	1.35 (1.18, 1.54)
				Stroke	1.22 (1.10, 1.36)
(Van Hemelrijck et al. 2010)	76600 males with prostate cancer	3.8 y*	GnRH agonist†	IHD	1.30 (1.17, 1.45)
				MI	1.28 (1.11, 1.47)
				Stroke	1.27 (1.12, 1.43)
				Heart failure	1.46 (1.28, 1.67)
				Arrhythmia	1.27 (1.10, 1.47)

Abbreviations: HR - hazard ratio; CI - confidence interval; ADT - androgen deprivation therapy; IHD - ischaemic heart disease; MI - myocardial infarction; SCD - sudden cardiac death. *Mean follow-up; †GnRH agonist users were compared to the general population